Aegera
Biotech
Menu
Our portfolio
Rosetta invests in companies that have the potential to transform medical care.
Our focus is on companies at late-preclinical or clinical stages of development that are developing innovative therapeutics, medical devices or diagnostics.
We manage a series of venture funds, primarily with a secondary investment focus, and currently are actively managing our funds IV and V. Our portfolio companies are located across Europe, North America and Asia.
A selection of our portfolio of companies is shown below.
Ambit
Pharmaceutical
Aprea
Pharmaceutical
Asarina
Biotech
Biosergen
Biotech
Carrick Therapeutics
Pharmaceutical
Catalyst Biosciences
Pharmaceutical
Curalogic
Pharmaceutical
Cytochroma
Pharmaceutical
Destiny Pharma
Biotech
Dilafor
Biotech
Enobia
Pharmaceutical
Eyesense
Medical Device
Forward Pharma
Biotech
Gemin X
Pharmaceutical
Glycomimetics
Biotech
Immunocore
Biotech
Inivata
Biotech
JenaValve
Medtech
Mereo Biosciences
Biotech
Mission Therapeutics
Biotech
Modus
Biotech
Novagali Pharma
Biotech
NovImmune
Pharmaceutical
Onconova
Pharmaceutical
Oxular
Biotech and Drug Delivery
Paratek
Biotech
Promimic
Medical Device
Promore Pharma
Biotech
PTC-Therepeutics
Pharmaceutical
ReNeuron
Biotech
Resonant Medical
Medical Device
Rose Pharma
Biotech
Sequana Medical
Medtech
Sonendo
Medtech
Tepha
Medical Device
Topigen
Biotech
Tranzyme Pharma
Pharmaceutical
Velico
Medical Device
Veloxis
Pharmaceutical
Find out more
Our people
We are headquartered in the UK and our team is located across Europe and Asia, providing us with broad geographic networks that have proven useful to support our portfolio companies.
About us
We are a specialist UK-based life science venture capital firm that invests globally to build leading healthcare companies and breakthrough technologies that can deliver benefits to human lives.
